Redhill Biopharma Ltd

Redhill Biopharma insider holdings reveal strong long‑term confidence as executives hold significant RSUs and options, signaling potential upside tied to upcoming clinical milestones.

Redhill Biopharma’s chief business officer holds 305 million shares and RSUs, showing insider confidence amid a steep share decline – a bullish signal for investors.

Redhill Biopharma’s CEO keeps his stake steady, signalling confidence amid a volatile share price and a deep‑discounted market cap. Insider stability hints at long‑term optimism as the company pursues late‑stage trials.